Tag: Boehringer Ingelheim

Boehringer Ingelheim’s SENVELGO gets EU marketing authorization for feline diabetes treatment

businessnewstoday- November 23, 2023

The European Commission has granted marketing authorization to Boehringer Ingelheim for SENVELGO (active ingredient: velagliflozin), a groundbreaking development in the treatment of feline diabetes across ... Read More

Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition

businessnewstoday- November 22, 2023

Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 ... Read More

Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial

businessnewstoday- November 5, 2023

Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a ... Read More

Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks

businessnewstoday- October 2, 2023

The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant development announced jointly by Boehringer Ingelheim and ... Read More

Lupin, Mark Cuban’s Cost Plus Drugs and COPD Foundation boost COPD treatment access

businessnewstoday- September 6, 2023

In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost ... Read More

Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim

businessnewstoday- August 19, 2023

In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ... Read More

Survodutide shows promising results in Phase 2 study for weight loss in obese people

businessnewstoday- June 24, 2023

Boehringer Ingelheim and Zealand Pharma have announced further data showcasing the superior efficacy of survodutide (BI 456906) compared to placebo in individuals with overweight or ... Read More

Lupin clinches FDA approval for generic Spiriva HandiHaler

businessnewstoday- June 21, 2023

Indian pharma titan Lupin has announced receiving approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Tiotropium Bromide ... Read More

Glenmark Pharmaceuticals gets FDA approval for Nintedanib Capsules

pallavi123- June 28, 2021

Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA) for Nintedanib Capsules, 100mg, and 150mg. Nintedanib ... Read More

Glenmark Pharmaceutical launches Tiogiva in UK for COPD treatment

pallavi123- June 15, 2021

Glenmark Pharmaceutical has announced the UK launch of Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI), for the treatment of chronic obstructive ... Read More